Loading...
Loading...
Watson Pharmaceuticals, Inc.
WPI today announced that it has completed the acquisition of
Belgium-based Uteron Pharma SA for $150 million in cash up front, and up to
$155 million in potential future milestone payments. The acquisition of
Uteron expands Watson's Global Brands pipeline of Women's Health products
including two potential near term global commercial opportunities in
contraception and infertility, and one novel oral contraceptive, projected to
launch globally in 2018. Several additional products in earlier stages of
development are also included in the acquisition. The Company said the
transaction is expected to be minimally dilutive to non-GAAP earnings in 2013
and 2014, and accretive in 2015.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in